Treatment Management and the
|
|
- Jonathan Hampton
- 5 years ago
- Views:
Transcription
1 Evidence-based Sequenced Treatment Management and the 2010 APA Practice Guideline George I. Papakostas, MD Director, Treatment-Resistant Depression Studies Department of Psychiatry Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School
2 Faculty Disclosure The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: George I. Papakostas, MD Consulting fees: Cephalon Inc., Dey Pharma, Otsuka Pharmaceuticals, PAMLAB LLC, and Ridge Diagnostics (formerly known as Precision Human Biolaboratories) Contracted research: AstraZeneca PLC, Forest Pharmaceuticals, the National Institute of Mental Health (NIMH), PAMLAB LLC, Pfizer Inc., and Ridge Diagnostics Honoraria: Astra Zeneca PLC, Brainsway Ltd, Bristol-Myers Squibb Company, Cephalon Inc., Dey Pharma, L.P., Eli Lilly Co., GlaxoSmithKline, Otsuka Pharmaceuticals, PAMLAB LLC, Ridge Diagnostics
3 Talking Point Implement evidence-based sequenced management strategies based on the 2010 American Psychiatric Association (APA) Practice Guideline to enhance clinical decision-making i for adult patients t with Major Depressive Disorder (MDD)
4 Goal of Acute Phase Treatment: Sustained Remission Response 50% improvement in symptoms Allows for significant residual symptoms Vs Remission At least 3 weeks of the absence of both sad mood and reduced interest No more than 3 remaining symptoms American Psychiatric Association. Am J Psychiatry. 2010;167:1-152.
5 APA Guideline: Timing of Intervention Goal of Acute Phase of therapy is remission 1 Measurement-based care is key 1 Delay in achieving remission of symptoms is characteristic 2,3 Discontinuing a treatment prematurely (ie, <4 weeks) due to lack of efficacy alone may deprive some patients of a potentially effective therapy Waiting too long in the face of complete non-response (ie, >8 weeks) may unnecessarily increase patient s exposure to an ineffective therapy and, ultimately, delay improvement 1. American Psychiatric Association. Am J Psychiatry. 2010;167: Trivedi MH, et al. Am J Psychiatry. 2006;163: Quitkin FM, et al. Am J Psychiatry. 2003;160: APA=American Psychiatric Association.
6 APA Guideline: Assessment of Therapeutic Failure Adequacy of treatment Dose, duration, quality of therapy Appropriateness of diagnosis Bipolar disorder, psychotic features Adequacy of diagnosis Psychiatric/medical co-morbidity Compliance and tolerability Pharmacokinetic factors American Psychiatric Association. Am J Psychiatry. 2010;167: APA=American Psychiatric Association.
7 Pharmacologic Treatment Approaches Increase dosage Switching Augmentation Addition of a non-antidepressant agent to enhance the effect of the antidepressant Combination Addition of a second antidepressant agent to enhance the effect of the original i antidepressant t
8 Augmentation, Combination, Switching Augmentation and combination Avoid loss of any therapeutic benefits from first-line agent No risk of withdrawal symptoms May target side effects of first-line treatment Switching Better compliance Lower risk of drug interactions Resolution of side effects Lower cost?
9 General Guides: 2+ Line Approaches Partial response (vs non-response) Favors Retention of Initial Agent Augmentation Combination Dose-increase Poor tolerability (vs good tolerability) Favors discontinuation of initial agent Switching Knowledge of relative efficacy and tolerability of 2 nd + line strategies key to guiding treatment selection
10 Atypical Antipsychotic Augmentation in Randomized Clinical Trials Atypical Study Duration Antipsychotic Antidepressant Shelton et al Olanzapine Fluoxetine Shelton et al Olanzapine Fluoxetine Corya et al Olanzapine Fluoxetine Keitner et al Risperidone Various Khullar et al Quetiapine SSRI or SNRI Mattingly et al Quetiapine SSRI or SNRI McIntyre et al Quetiapine SSRI or SNRI Thase et al Olanzapine Fluoxetine Thase et al Olanzapine Fluoxetine Gharabawi et al Risperidone Various Papakostas GI, et al. J Clin Psychiatry. 2007;68: SNRI=serotonin-norepinephrine reuptake inhibitor. SSRI=selective serotonin reuptake inhibitor.
11 Atypical Antipsychotic Augmentation in TRD: Meta-analysisanalysis of 10 RCTs 100% 80% N=1500 Remission (P<0.05) Pe ercent 60% 40% 47.4% 37.0% Discontinued for intolerance (P<0.05) 20% 22.3% 12.0% 0% Atypical Placebo Papakostas GI, et al. J Clin Psychiatry. 2007;68: RCT=randomized control trial. TRD=treatment-resistant depression.
12 Aripiprazole Augmentation in TRD: Results From 3 Placebo-Controlled Trials 100% 80% Aripiprazole Placebo Remis ssion (%) 60% 40% 20% P<0.05 P< % 25.4% 15.7% 15.2% P< % 18.9% 0% 1 Study 1 2 Study 2 3 Study 3 N=362 N=381 N= Berman RM et al. J Clin Psychiatry. 2007;68: Marcus RN et al. J Clin Psychopharmacol. 2008;28: Berman RM et al. CNS Spectr. 2009;14: TRD=treatment-resistant depression.
13 Augmentation With Atypical Antipsychotics Aripiprazole 5-15 mg, olanzapine 5-15 mg, quetiapine mg, risperidone mg Advantages Best studied d strategy t Disadvantages (varies by agent) Tolerability Neuroendocrine (prolactin) Metabolic (weight, lipids, glucose regulation) Extrapyramidal symptoms (tardive dyskinesia, neuroleptic malignant syndrome, akathisia, parkinsonism, dystonic reactions) Efficacy as second-line treatment? Long-term efficacy?
14 Lithium Augmentation of TCAs Study N Duration Efficacy Heninger et al weeks Lithium > Placebo Kantor et al days Lithium = Placebo Zusky et al weeks Lithium = Placebo Schopf et al week Lithium > Placebo Stein and Bernadt weeks Lithium = Placebo Joffe et al weeks Lithium > Placebo Nierenberg et al weeks Lithium = Placebo TCAs=tricyclic antidepressants. Heninger GR, et al. Arch Gen Psychiatry. 1983;40: Kantor D, et al. Can J Psychiatry. 1986;31: Zusky PM, et al. J Clin Psychopharmacol. 1988;8: Schopf J, et al. Pharmacopsychiat. 1989;22: Stein G, Bernadt M. Br J Psychiatry. 1993;162: Joffe RT, et al. Arch Gen Psychiatry. 1993;50: Nierenberg AA, et al. J Clin Psychopharmacol. 2003;23:92-95.
15 Lithium Augmentation of SSRIs Study N Duration Efficacy Katona et al weeks Lithium = Placebo Baumann et al week Lithium > Placebo Katona CL, et al. Br J Psychiatry. 1995;166: Baumann P, et al. J Clin Psychopharmacol. 1996;16: SSRI=selective serotonin reuptake inhibitors.
16 Augmentation With Lithium Doses mg daily Advantages Pooled odds ratio of response during lithium augmentation compared with placebo is 3.31 (95% CI, ) Disadvantages Margin of efficacy vs dose increase, other strategies All positive placebo-controlled controlled studies of short duration Paucity of studies on newer agents Risk of toxicity and need for blood monitoring
17 Mirtazapine/Mianserin Combination Study N Duration Antidepressant Efficacy Maes et al weeks SSRI Mianserin > Placebo Ferreri et al weeks SSRI Mianserin > Placebo Carpenter et al weeks SSRI Mirtazapine > Placebo Licht and Qvitzau weeks SSRI Mianserin = Placebo Maes M, et al. J Clin Psychopharmacol. 1999;19: Ferreri M, et al. Acta Psychiatr Scand. 2001;103: Carpenter LL, et al. Biol Psychiatry. 2002;51: Licht RW, Qvitzau S. Psychopharmacology (Berl). 2003;161: SSRI=selective serotonin reuptake inhibitors.
18 Mirtazapine/Mianserin Combination (cont d) mg at bedtime Advantages Strong efficacy data May help with insomnia Disadvantages Weight gain Sedation Agranulocytosis (very rare)
19 Augmentation With Pindolol Study N Duration Antidepressant Efficacy Maes et al weeks trazodone Pindolol > Placebo* Maes et al weeks fluoxetine Pindolol > Placebo* Perez et al weeks SSRIs/TCAs Pindolol = Placebo Perry et al days SSRI Pindolol = Placebo *Both treatment-resistant resistant and nontreatment-resistant resistant patients were enrolled. Maes M, et al. J Clin Psychopharmacol. 1999;19: Maes M, et al. J Affect Disord. 1996;41: Perez V, et al. Arch Gen Psychiatry. 1999;56: Perry EB, et al. J Clin Psychiatry. 2004;65: SSRI=selective serotonin reuptake inhibitors. TCAs=tricyclic antidepressants.
20 Pindolol Augmentation of SSRIs mgtid Advantages May accelerate response to SSRIs Disadvantages No difference from placebo in 2 largest studies Increased irritability Ballesteros J, Callado LF. J Affect Disord. 2004;79: Brousse G, et al. Encephale. 2003;29: Perez V, et al. Arch Gen Psychiatry. 1999;56: Maes M, et al. J Clin Psychopharmacol. 1999;19: SSRI=selective serotonin reuptake inhibitors. tid=3 times per day.
21 Testosterone Augmentation Pilot study (gel) in men (n=22) with testosterone levels 350 ng was positive 1 Subsequent study in men (n=18) was negative 2 A third study in men (n=26) utilizing intramuscular administration also was negative 3 Subsequent study in men (n=100) was negative 4 1. Pope HG, et al. Am J Psychiatry. 2003;160: Orengo CA, et al. J Geriatr Psychiatry Neurol. 2005;18: Seidman SN, et al. J Clin Psychopharmacol. 2005;25: Pope HG, et al. J Clin Psychopharmacol. 2010;30:
22 Augmentation With Omega-3 Fatty Acids Study N Duration Efficacy Nemets et al weeks E-EPA (2 g) > Placebo Peet and Horrobin weeks E-EPA (1 g) > Placebo * Su et al weeks Omega-3 FA > Placebo Lesperance et al weeks Omega-3 FA = Placebo * But not 2 g or 4 g E-EPA. 440 mg EPA plus 220 mg DHA mg EPA plus 150 mg DHA. DHA=docasahexaenoic acid. E-EPA=ethyl-eicosapentaenoicEPA=ethyl eicosapentaenoic acid. FA=fatty acid. Nemets B, et al. Am J Psychiatry. 2002;159: Peet M, et al. Arch Gen Psychiatry. 2002;59: Su KP, et al. Eur Neuropsychopharmacol. 2003;13: Lesperance F, et al. J Clin Psychiatry. 2011;72:
23 Augmentation With Omega-3 Fatty Acids (cont d) Advantages Tolerability Acceptability May possess other health-promoting benefits (CV?) Disadvantages Optimal dose unknown (1 g/d EPA+DHA) Cost CV=cardiovascular. DHA=docasahexaenoic acid. EPA=eicosapentaenoic acid.
24 Triodothyronine (T3) Augmentation of TCAs Study N Duration Efficacy Coppen et al weeks T3 > Placebo Gitlin et al weeks T3 = Placebo Joffe et al weeks T3 > Placebo Gitlin MJ, et al. J Affect Disord. 1987;13: Joffe RT, et al. Arch Gen Psychiatry. 1993;50: Coppen A, et al. Arch Gen Psychiatry. 1972;26: TCAs=tricyclic antidepressants.
25 Augmentation With T mg qd Advantages May accelerate clinical response Disadvantages All placebo-controlled controlled studies involve TCAs Among the 4 randomized double-blind studies, pooled effects were not significant (P>0.05) qd=once daily. T3=triodothyronine. TCAs=tricyclic antidepressants.
26 Augmentation With Modafinil mg qd Advantages Efficacy demonstrated in 2 trials when pooled May resolve depressive symptoms in patients who also present with residual somnolence and fatigue Useful for residual somnolence Disadvantages Unclear efficacy in patients without fatigue and sleepiness Unclear efficacy in patients with insomnia DeBattista C, et al. J Clin Psychiatry. 2003;64: Fava M, et al. J Clin Psychiatry. 2005;66: Fava M, et al. Ann Clin Psychiatry. 2007;19: qd=once daily.
27 Buspirone Augmentation of SSRIs mg bid Advantages Disadvantages 2 placebo-controlled studies showed buspirone equivalent to placebo Landén M, et al. J Clin Psychiatry. 1998;59: Appelberg BG, et al. J Clin Psychiatry. 2001;62: bid=twice daily. SSRI=selective serotonin reuptake inhibitors.
28 Augmentation With OROS Methylphenidate OROS methylphenidate mg/d Advantages May help with fatigue, apathy, and somnolence May help with comorbid ADHD Disadvantages 2 negative studies published to date Potential for abuse Ravindran AV, et al. J Clin Psychiatry. 2008;68: Patkar AA, et al. J Clin Psychopharmacol. 2006;26: ADHD=attention-deficit/hyperactivity disorder. OROS=osmotic-release oral system.
29 Augmentation With L-methylfolate 100% 80% L-methylfolate augmentation Antidepressant Monotherapy Respo onse (%) 60% 40% 20% 18.3% 24.1% 35.2% * 17.6% 0% Study I, 7.5mg daily N=150 Study II, 15mg daily N=75 *P<0.05 Fava M, et al. J Clin Psychiatry. 2011;72:e25.
30 Augmentation With SAMe 100% SAMe augmentation (n=39) 80% Antidepressant Monotherapy (n=34) Pati ients (%) 60% 40% * 35.8% 46.1% * 20% 11.7% 17.6% 0% Response Remission *P<0.05 Papakostas GI, et al. Am J Psychiatry. 2010:167: SAMe=S-Adenosyl Methionine.
31 STAR*D Level 2: Addition of Bupropion vs Buspirone to Citalopram for TRD in a Randomized d Study 100% Discontinued for intolerance N=565 (P<0.05) 80% Remission (QIDS) (P=NS) ents (%) Pati 60% 40% 39.0% 33.0% 20% 12.5% 20.6% 0% Bupropion Buspirone Trivedi MH et al. N Engl J Med. 2006;35: QIDS=Quick Inventory of Depression Symptomatology. STAR*D=Sequenced Treatment Alternatives to Relieve Depression. TRD=treatment-resistant depression.
32 STAR*D Level 2: CBT vs Pharmacotherapy 100% 80% P >0.05 for both analyses CBT Pharmacotherapy ) Rem mission (% 60% 40% 20% 33.3% 23.1% 25.0% 27.9% 0% Augmentation Switch Thase ME, et al. Am J Psychiatry. 2007;64: STAR*D=Sequenced Treatment Alternatives to Relieve Depression. CBT=cognitive-behavioral therapy.
33 Switching From SSRI to SSRI vs Non-SSRI (Bupropion, Venlafaxine, Sertraline) Study Sponsor Duration (Weeks) Lead-in SSRI Switch SSRI Switch Non-SSRI Poirier and Boyer 1999 Wyeth 4 Various Paroxetine Venlafaxine Lenox-Smith and Jiang 2008 Wyeth 12 Various Citalopram Venlafaxine ER Thase et al 2001 Organon 8 Various Sertraline Mirtazapine Rush et al 2006 NIMH 14 Citalopram Sertraline Venlafaxine ER Rush et al 2006 NIMH 14 Citalopram Sertraline Bupropion SR N=1496 Poirier MF, Boyer P. Br J Psychiatry. 1999;175: Lenox-Smith AJ, Jiang Q. Int Clin Psychopharmacol. 2008;23: Thase ME, et al. Mirtazapine versus sertraline after SSRI non-response. Presented at the New Clinical Drug Evaluation Unit of the National Institute of Mental Health Annual Meeting. May 2001; Phoenix, AZ. Rush AJ, et al. N Engl J Med. 2006;354: ER=extended release. NIMH=National Institute of Mental Health. SR=sustained release. SSRI=selective serotonin reuptake inhibitors.
34 Treatment of SSRI-Resistant MDD: Meta-analysis Comparing Within (2nd SSRI) vs Across (Non-SSRI) Class Switches Pati ients (%) 100% Remission (HDRS) (P<0.05) Discontinued for Intolerance 80% (P=0.1) 60% 40% 28.0% 23.5% 20% 17.7% 7% 11.5% 0% SSRI Non-SSRI *N=1496; 4 RTCs. Papakostas GI, et al. Biol Psychiatry. 2008;63: HDRS=Hamilton Depression Rating Scale. SSRI=selective serotonin reuptake inhibitors.
35 Switching Imipramine (TCA)-Resistant MDD to Phenelzine (MAOIs) and Vice Versa (Crossover): Two Randomized, Double-Blind Studies 100% Imipramine Phenelzine Resp ponders (% %) 80% 60% 40% P< % P< % 67.3% 40.9% 20% 0% 1 2 Study 1 Study 2 N=40 N=68 1. McGrath PJ, et al. Psychopharmacol Bull. 1987;23: McGrath PJ, et al. Am J Psychiatry. 1993;150: MAOI=monoamine oxidase inhibitor. TCA=tricyclic antidepressant.
36 STAR*D Level 3 Switch Pati ients (%) 100% 80% 60% 40% Remission (QIDS) N=235 (P=NS) Discontinued for intolerance (P=NS) 36.2% 34.2% 20% 0% 12.4% Nortriptyline py 8.0% Mirtazapine Fava M, et al. Am J Psychiatry. 2006;163: QIDS=Quick Inventory of Depression Symptomatology. STAR*D=Sequenced Treatment Alternatives to Relieve Depression.
37 Refractory Depression: Choices Electroconvulsive therapy Vagus nerve stimulation Deep brain stimulation Variable data for efficacy Timing i for introduction ti depending di upon Refractoriness of Illness Use in past episodes Patient preference Availability
38 Placebo Enhancement Remember: psychotherapy, antidepressants, somatic therapies are part of the reason why patients improve! Strategies for placebo enhancement Assuage fears, worry, and embarrassment about illness Work on problem-solving skills Plan resumption of pleasurable activities Provide hope Involve patients in treatment decisions patient preference! Supportive components of MDD care Team approach Use of a case manager Assess to a psychiatrist Adherence monitoring and support Provide education to patient and family MDD=major depressive disorder.
39 Conclusion Several pharmacologic strategies exist for TRD Augmentation with atypical antipsychotics best studied Mirtazapine/mianserin as well as omega-3 fatty acids augmentation also possess considerable efficacy data Lithium, T3 offer mixed data CBT, bupropion, modafinil, L-methylfolate, SAMe promising and require replication Pindolol, buspirone, testosterone (in men), and methylphenidate do not appear to be very useful TRD=treatment-resistant depression. CBT=cognitive-behavioral therapy. SAMe=S-adenosyl methionine. T3=triodothyronine.
40 Conclusion (cont d) Switching to an SNRI, an alternative SSRI, or bupropion in SSRI-resistant MDD supported by reasonable efficacy data Switching to MAOIs provided mixed data Switching to TCAs supported by weak data Remission rates with monotherapy were low after stage 2 SNRI=serotonin-norepinephrine reuptake inhibitor. SSRI=selective serotonin reuptake inhibitor. MAOI=monoamine oxidase inhibitor. TCA=tricyclic antidepressant.
41 Conclusion (cont d) In the face of TRD, it is essential to Ensure proper diagnosis Ensure the adequacy of the antidepressant trial Rule out relapse Therapeutic issues to consider in each individual case Potential loss of partial benefit from the failed trial as well as the risk of withdrawal symptoms may reduce the feasibility of switching strategies Presence of significant side effects from the antidepressant itself as well as the risk of drug interactions may reduce the feasibility of augmentation/combination strategies TRD=treatment-resistant depression.
Augmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationKey Slides. Progress in Schizophrenia and Bipolar Disorder: Update Numbers of Patients at each Level 3,671 1,
Of Ultimate Responders, 2/3 Responded by Week 6 What Have We Learned From STARD? 3 25 2 Percent 15 1 5 17.8 65.2% 24.5 22.9 N = 2876 Response = 5% QIDS-SR 16 11.5 11. 7.6 4.9 2 4 6 8 1 12 >13 Weeks Trivedi
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationTreating treatment resistant depression
Treating treatment resistant depression These slides are the intellectual property of Ian Anderson and must not be reproduced Ian Anderson Neuroscience and Psychiatry Unit University of Manchester and
More informationTreatment strategies in major depression What to use when?
Treatment strategies in major depression What to use when? Michael Bauer, MD, PhD Professor and Chair of Psychiatry University Hospital Carl Gustav Carus Technische Universität Dresden Germany First-line
More informationThe scope of the problem. Literature review
Past Year: Novartis Ever: Alkermes, Amylin, Behringer- Ingelheim, Biovail, Bristol-Myers Squibb, Eli Lilly, Embryon, GlaxoSmithKline, Merck, Organon, Park-Davis, Pfizer, Sanolfi-Aventis, Smith-Kline Beacham,
More informationA PATIENT-CENTERED APPROACH TO THE MANAGEMENT OF DEPRESSION
Education Partner A PATIENT-CENTERED APPROACH TO THE MANAGEMENT OF DEPRESSION November 15, 212 Boston, Massachusetts Session 3: A Patient-Centered Approach to the Management of Depression: Achieving and
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More informationWith Adult Major Depressive Disorder: A Clinical and Economic Assessment
Atypical Antipsychotics to Achieve Remission With Adult Major Depressive Disorder: A Clinical and Economic Assessment Charles L. Raison, MD Associate Professor Department of Psychiatry University of Arizona
More informationApproaches to Treatment Resistant Depression (TRD): An Update Focusing on Studies Published in
An Update Focusing on Studies Published in 2011-2013 Albert Yeung, M.D., ScD Associate Professor of Psychiatry Harvard Medical School This is a summary of a review of approaches to treatment resistant
More information3. Depressione unipolare
3. Depressione unipolare Depressione unipolare con mancata risposta al trattamento con SSRI Question: Should switching from SSRIs to another antidepressant class vs switching within class (SSRIs) be used
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationTreatment Resistant Depression: A Systematic Approach to Management
Treatment Resistant Depression: A Systematic Approach to Management Michael E. Thase, M.D. University of Pennsylvania School of Medicine Philadelphia Veterans Affairs Medical Center University of Pittsburgh
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationCurrent. p SYCHIATRY. Treatment-resistant. Switch or augment? Choices that
Treatment-resistant Switch or augment? Choices that depression improve response rates When initial antidepressant therapy fails, an algorithmic approach to medication is more effective than treatment-as-usual.
More informationDrug Surveillance 1.
22 * * 3 1 2 3. 4 Drug Surveillance 1. 6-9 2 3 DSM-IV Anxious depression 4 Drug Surveillance GPRD A. (TCA) (SSRI) (SNRI) 20-77 - SSRI 1999 SNRI 2000 5 56 80 SSRI 1 1999 2005 2 2005 92.4, 2010 1999 3 1
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationGraylands Hospital Drug Bulletin
Graylands Hospital Drug Bulletin Antidepressant Combination and Augmentation Strategies North Metropolitan Area Mental Health Service October 2008 Vol 15 No.4 ISSN 1323-1251 Introduction Depression is
More informationAugmentation treatment in major depressive disorder: focus on aripiprazole
EXPERT OPINION Augmentation treatment in major depressive disorder: focus on aripiprazole J Craig Nelson 1 Andrei Pikalov 2 Robert M Berman 3 1 University of California San Francisco, San Francisco, California,
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More information1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A.
1 1 Evidence-based pharmacotherapy of major depressive disorder Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. Nierenberg Massachusetts General Hospital and Harvard University, Boston,
More informationComorbid Conditions and Antipsychotic Use in Patients with Depression
Comorbid Conditions and Antipsychotic Use in Patients with Depression Thomas W. Heinrich, MD Professor of Psychiatry and Family Medicine Director, Division of Consultation-Liaison Psychiatry Medical College
More informationTreatment-resistant depression in primary care
Treatment-resistant depression in primary care Interprofessional CME, October 2017 Brian J. Mickey, MD, PhD Associate Professor School of Medicine Department of Psychiatry Disclosures Speakers bureau:
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationManagement of. Depression: Some observations
Management of Psychobiology Research Group Depression: Some observations Hamish McAllister-Williams Reader in Clinical Psychopharmacology, Newcastle University Hon. Consultant Psychiatrist, Regional Affective
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationThe following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online.
Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by an educational
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationClinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
More informationANXIOUS DEPRESSION. Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University
ANXIOUS DEPRESSION Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University NED H. KALIN, MD Disclosures!! Research/Grants: None!! Speakers Bureau: None!! Consultant: None!!
More informationMentoring Session: Participant Cases
Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationNon-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450
James A. Bourgeois, O.D., M.D. Vice Chair Clinical Affairs and Director, CL Service University of California San Francisco Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450 Localize! Sequence! 1
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationEvidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
SPECIAL ARTICLE Psychiatry & Psychology http://dx.doi.org/10.3346/jkms.2014.29.4.468 J Korean Med Sci 2014; 29: 468-484 -Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
More informationTHE ANTIDEPRESSANT PRIMER PETER ROY-BYRNE MD PROFESSOR OF PSYCHIATRY UNIVERSITY OF WASHINGTON
THE ANTIDEPRESSANT PRIMER PETER ROY-BYRNE MD PROFESSOR OF PSYCHIATRY UNIVERSITY OF WASHINGTON OUTLINE Do Antidepressants Work? Are all Antidepressants the Same? Importance of Dose and Treatment Duration
More informationRecognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD)
Objectives Recognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD) Discuss the burden of MDD on the individual and society Explore the negative impact of residual symptoms Identify
More informationEarly response as predictor of final remission in elderly depressed patients
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry (2009) Published online in Wiley InterScience (www.interscience.wiley.com).2261 Early response as predictor of final remission in
More informationFamily Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University
APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure
More informationers_practice_parameter.pdf
These Guidelines were based in part from on following: Treatment of Patients With Major Depressive Disorder from the American Psychiatric Association (APA) that was amended by the following Guideline Watch
More informationRecent Advances in the Treatment of Major Depression
Recent Advances in the Treatment of Major Depression Antidepressant Drugs: Unmet Needs in 2015 Limited efficacy (~ 10-20% advantage vs PBO in RCTs) Intolerable side effects for some Inconsistent effects
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationCME. Pharmacotherapy of Depression in Older Adults. Introduction. Major Depression
CME Pharmacotherapy of Depression in Older Adults This CME learning activity is available at www.geriatricsandaging.ca/cme_page.htm. Participating physicians are entitled to one () MAINPRO-M credit by
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationFlorida Best Practice Medication Guidelines Principles of Practice for Adults
http://flmedicaidbh.fmhi.usf.edu Florida Best Practice Medication Guidelines Principles of Practice for Adults 1. Goal of the Guidelines Persistent gaps exist in the quality of mental health care delivered
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationA Review of the Role of Antipsychotics as an Augmentation Agent or Treatment Option for Patients with Treatment Resistant Unipolar Depression
International Journal of Emergency Mental Health and Human Resilience, Vol. 17, No.2, pp. 476-480, ISSN 1522-4821 A Review of the Role of Antipsychotics as an Augmentation Agent or Treatment Option for
More informationDaniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School
Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical
More informationPharmacotherapy of Depression: State of the Art and Future Directions Michael E. Thase, MD
Pharmacotherapy of Depression: State of the Art and Future Directions Michael E. Thase, MD University of Pennsylvania School of Medicine Philadelphia Veterans Affairs Medical Center University of Pittsburgh
More informationABSTRACT ORIGINAL RESEARCH. Roger S. McIntyre. Emmanuelle Weiller
Adv Ther (2015) 32:429 444 DOI 10.1007/s12325-015-0207-3 ORIGINAL RESEARCH Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationAntidepressant Medication Therapy in Primary Care July 25, 2013
New York State Collaborative Care Initiative Antidepressant Medication Therapy in Primary Care July 25, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
More informationOptimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice
Review Article www.cmj.ac.kr Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice Changsu Han 1#, Sheng-Min Wang 2#,
More informationAntidepressant Therapy 2016
Antidepressant Therapy 2016 Michael E. Thase, MD University of Pennsylvania School of Medicine Philadelphia Veterans Affairs Medical Center University of Pittsburgh Medical Center thase@mail.med.upenn.edu
More informationPharmacological treatment of anxiety disorders where is
Pharmacological treatment of anxiety disorders where is the room for improvement? David S Baldwin, Professor of Psychiatry BAP Masterclass, 15 th April 2011 dsb1@soton.ac.uk Declaration of interests (last
More informationPrescribing Medications for Anxiety and Depression (without getting anxious and depressed)
Prescribing Medications for Anxiety and Depression (without getting anxious and depressed) Stephen Warnick Jr., M.D. Assistant Professor Departments of Family Medicine and Psychiatry Disclosures None 2
More informationMr. E, age 37, has a 20-year history
Antipsychotics for obsessive-compulsive disorder: Weighing risks vs benefits Taylor Modesitt, PharmD, Traci Turner, PharmD, BCPP, Lindsay Honaker, DO, Todd Jamrose, DO, Elizabeth Cunningham, DO, and Christopher
More informationDepression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
More informationBetter But Not Well: Addressing Inadequate Response in Patients With Major Depressive Disorder
Handout for the Neuroscience Education Institute (NEI) online activity: Better But Not Well: Addressing Inadequate Response in Patients With Major Depressive Disorder Learning Objectives List common factors
More informationAugmentation Treatments with Second-generation Antipsychotics to Antidepressants in Treatment-resistant Depression
CNS Drugs (2013) 27 (Suppl 1):S11 S19 DOI 10.1007/s40263-012-0029-7 REVIEW ARTICLE Augmentation Treatments with Second-generation Antipsychotics to Antidepressants in Treatment-resistant Depression Masaki
More informationMental illness A Broad Overview. Dr H Pathmanandam March 2017
Mental illness A Broad Overview Dr H Pathmanandam March 2017 Introduction Mental disorders are common in primary and secondary care Many are not recognised and not treated Some receive unnecessary or inappropriate
More information#CHAIR2016. September 16 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 16 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Depression in Children and Adolescents Karen Dineen Wagner, MD, PhD University of Texas Medical Branch Galveston, TX Karen Dineen
More informationSetting ambitious goals for patients with depression with a focus on functional recovery
Setting ambitious goals for patients with depression with a focus on functional recovery The role of the overlooked cognitive symptoms in the treatment of depression Dr Andreas Papadopoulos Locum Consultant
More informationVA/DoD Clinical Practice Guideline for Management of Post Traumatic Stress. Core Module
VA/DoD Clinical Practice Guideline for Management of Post Traumatic Stress Core Module Module A Acute Stress Continue Treatment for ASD Treatment for ACUTE Stress Disorder Module B PTSD Continue Treatment
More informationDrugs for Emotional and Mood Disorders Chapter 16
Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Medicine: Update 2010 Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco
More informationEffective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
More informationPanic disorder is a chronic and recurrent illness associated
CLINICAL PRACTICE GUIDELINES Management of Anxiety Disorders. Panic Disorder, With or Without Agoraphobia Epidemiology Panic disorder is a chronic and recurrent illness associated with significant functional
More informationPsychopharmacology of Autism Spectrum Disorder
Psychopharmacology of Autism Spectrum Disorder Christopher J. McDougle, MD Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral Hospital
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationDisclosure Information
Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety
More informationOptimal Treatment of Anxiety Disorders
Optimal Treatment of Anxiety Disorders Franklin R. Schneier, MD Co-Director, Anxiety Disorders Clinic Research Psychiatrist New York State Psychiatric Institute Special Lecturer in Psychiatry Columbia
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More information